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Surveillance, Bill & Melinda Gates Foundation, Seattle, Washigton; 5Enteric and Diarrheal Diseases, Bill & Melinda Gates Foundation, Seattle,
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For us, the authors of this viewpoint, our respective journeys
related to typhoid fever span almost three decades, from an
early exposure to the severe morbidity associated with drug-
resistant typhoid1,2 to assessment of priorities for dealingwith
the burdenof a neglected disorder.3 Despite the fact that there
have been numerous,mostlymodeled, global estimates of the
burden of typhoid over the past several decades,4–6 progress
in addressing this illness has beenwoefully slow. This is partly
a result of limited nationally representative estimates from
low- and middle-income countries and general mispercep-
tions that typhoid is largely preventable through socioeco-
nomic development and gains in environmental conditions,
such as sanitation and safe water, and that secular trends
suggest that the disease burden is decreasing.
A range of recent investments have aimed to improve our
collective knowledge of the real burden of typhoid in endemic
areas. These include the landmark studies conducted in Asia
under the International Vaccine Institute’s Diseases of the Most
Impoverished (DOMI) program. Although focused on evaluating
the feasibility of introducing the Vi polysaccharide vaccine, DOMI
provided population-based estimates from various endemic
countries in Asia.7 Although there is an agreement on progress
and reductions in typhoid burdens in parts of Latin America and
Southeast Asia over the last several decades, it is also notable
that typhoid remains a significant disorder in South Asia8 and
remains largely underestimated in sub-Saharan Africa.9 Also,
mostof thedatasetsused inglobalburdenestimates todatehave
largely reliedon theirmodelsonpopulation-basedestimates from
a limited number of countries and from special studies.
Recent gains in our collective knowledge of typhoid burden
havebeen supported to a large extent by investments from the
Bill & Melinda Gates Foundation in ground breaking studies of
the current typhoid burden, disease severity, and complica-
tions related to typhoid in Asia and Africa. Although there are
relatively few nationally representative population-based es-
timates, these recent studies have been reliant on methodol-
ogies from reliable laboratories and research institutions aiming
to provide robust estimates of blood culture proven typhoid.
The current exercise summarized in the supplement included in
this issue aimed to collect and synthesize information on blood
culture–proven typhoid from a range of referral hospitals and
laboratories to assess recent trends and correlates of typhoid.
Participating country teams evaluated information on various
social determinants and ecological trends, and assessed if
there were clear trends in the burden of culture proven typhoid
in the centers or populations evaluated.10
Despite several limitations of the country case studies,
which included relatively few nationally representative esti-
mates, several common findings emerged. Inmany instances,
although the typhoid burden has reduced in comparison with
the situation two decades ago (variable rates from annual re-
duction of 25% to an increase of 21%), rates seem to have
stabilized to low levels inmany countries. However, especially
among South Asian countries, the burden is still substantial,
accounting for 1–7% of all positive-blood cultures in South
Asia from the laboratories sampled.10 The observed trends of
typhoid also do not bear a clear relationship to economic
development, education, or changes in coverage of water and
sanitation interventions. Despite many common risks, no re-
lationship was observed with diarrheal disease burden or
trends. An important finding from the global review and case
studies was the emergence and persistence of antimicrobial
resistance (AMR) among typhoid isolates in several geogra-
phies, posing a challenge for access to appropriate therapy.
One would have expected that recent findings on typhoid
would be commensurate with measures in countries or glob-
ally to address these issues. Instead, there appears to have
beenmuch inaction and lackof a clear global policy to address
typhoid. Typhoid was largely ignored during the period of the
millennium development goals, given the singular focus on
maternal and child health; rather, it wasorphanedwithin global
organizations such as World Health Organization (WHO) and
United Nations International Children’s Fund. Much of the
typhoid-relevant work was relegated to the vaccines and bio-
logicals program at the WHO, and despite the fact that the
disease burden was disproportionately high among children,
including children under 5 years,11,12 none of the programs
within the WHO Child and Adolescent Health Department tar-
geted appropriate diagnosis and management of typhoid.
Several elements need to be considered in charting a way
forward for typhoid control. Notwithstanding the lack of clear
evidence thateconomicandsocialdevelopment lead to reduction
in disease burden in the short term, countries should continue to
invest in improved sanitation services and safe water as key in-
terventions. Formuchof SouthAsia thiswill mean addressing the
continuing problems of open defecation, safe water access, and
sewage disposal. Given population transition and demographic
changes and migration patterns, addressing the issues of urban
health, especially among slum dwellers, should be prioritized.
The emergence of AMR among strains of typhoid resistant
to both fluoroquinolones and third generation cephalospo-
rins13 poses special risks that must be addressed. This
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requires the development of protocols and appropriate
diagnostics for rapid detection of typhoid, especially multi-
drug resistant typhoid among febrile cases in endemic areas
(where common differential diagnoses include malaria and
viral infections such as dengue or chikungunya), as well as
financial support strategies to make this possible. The im-
portance of mainstreaming typhoid diagnosis and treatment
within routine health systems has been underscored in pre-
vious evaluations of health-care seeking patterns.14,15 Given
the current focus on universal health coverage and mecha-
nisms to provide safety nets to at-risk populations, this will
require development of strategies for mainstreaming the
management of typhoid fever, especially complicated cases
requiring referral. Antimicrobial resistance continues to need
global monitoring and, importantly, sharing of information
between countries. More recent super-resistant strains of
typhoid12,13 pose special problems, with higher morbidity
rates and significantly higher cost of therapy compared with
drug-sensitive infections.Managing such infections shouldgo
hand in hand with soundmonitoring and surveillance systems
to guide public policy and general practice in settings where
obtaining blood cultures in all febrile cases is not possible.
There is now much more hope that a concerted and com-
prehensive strategy for typhoid prevention and controlmay be
possible. These include the recent development of effective
typhoid conjugate vaccines,16,17 recommendation by the
WHO Strategic Advisory Group of Experts on Immunization
for the use of newer typhoid conjugate vaccines,18 and
the opening of a window for financing such initiatives by the
Global Vaccine Alliance. There is now a clear pathway for the
appropriate targeted useof the vaccineand its inclusionwithin
the expanded program of immunizations for infants in en-
demic areas and in campaigns targeting at risk populations.
Given the known risks of typhoid in conflict settings19 and
among displaced populations,20 appropriate immunization
strategies also include the use of typhoid vaccines in humani-
tarian settings as part of a comprehensive response strategy.
Given past experience with the use of typhoid vaccination in
outbreak situations,21 this could be a feasible response. The
recent successful use of a single-dose cholera vaccine in re-
sponse toanoutbreak inZambia22alsooffers a real opportunity
for the use of typhoid conjugate vaccine in such settings.
In line with emphasis within the sustainable development
goalsonpreventive strategiesanduniversal healthcoverage, it is
time to adopt a new action plan for the prevention and control of
typhoid fever.Thiswill requiresubstantial focusonadvocacyand
action in countries at the highest risk, with updated information
on disease burden, appreciation of specific contextual factors,
whichareamenable topublichealth investments, andpreventive
strategies including the newer vaccines. Not surprisingly, as
underscored by the country case studies in this supplement,
therewas little awareness in countries of the preventive potential
of vaccines,10 a status that the recent position statement from
WHO18 might change. Developing and implementing a com-
prehensive global action plan for typhoid encompassing a range
of preventive strategies and immunization approaches, and
appropriate diagnosis and treatment strategies is an essential
step in controlling typhoid within a generation.
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